Outlook Therapeutics Inc (NASDAQ: OTLK) kicked off on Friday, up 3.31% from the previous trading day, before settling in for the closing price of $5.14. Over the past 52 weeks, OTLK has traded in a range of $4.61-$18.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. While this was happening, its average annual earnings per share was recorded 3.43%. With a float of $15.23 million, this company’s outstanding shares have now reached $23.66 million.
Let’s determine the extent of company efficiency that accounts for 24 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Outlook Therapeutics Inc (OTLK) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Outlook Therapeutics Inc is 35.60%, while institutional ownership is 35.99%. The most recent insider transaction that took place on Sep 26 ’24, was worth 28,446. In this transaction Chief Financial Officer of this company bought 5,000 shares at a rate of $5.69, taking the stock ownership to the 5,946 shares. Before that another transaction happened on Mar 28 ’24, when Company’s Director bought 1,882 for $11.82, making the entire transaction worth $22,242. This insider now owns 5,049 shares in total.
Outlook Therapeutics Inc (OTLK) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1 earnings per share (EPS), higher than consensus estimate (set at -1.17) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.43% per share during the next fiscal year.
Outlook Therapeutics Inc (NASDAQ: OTLK) Trading Performance Indicators
Take a look at Outlook Therapeutics Inc’s (OTLK) current performance indicators. Last quarter, stock had a quick ratio of 1.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -10.75, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -2.27 in one year’s time.
Technical Analysis of Outlook Therapeutics Inc (OTLK)
Looking closely at Outlook Therapeutics Inc (NASDAQ: OTLK), its last 5-days average volume was 0.34 million, which is a drop from its year-to-date volume of 0.35 million. As of the previous 9 days, the stock’s Stochastic %D was 80.37%. Additionally, its Average True Range was 0.35.
During the past 100 days, Outlook Therapeutics Inc’s (OTLK) raw stochastic average was set at 15.09%, which indicates a significant decrease from 81.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.04% in the past 14 days, which was lower than the 66.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.40, while its 200-day Moving Average is $7.62. However, in the short run, Outlook Therapeutics Inc’s stock first resistance to watch stands at $5.45. Second resistance stands at $5.58. The third major resistance level sits at $5.83. If the price goes on to break the first support level at $5.07, it is likely to go to the next support level at $4.82. Now, if the price goes above the second support level, the third support stands at $4.69.
Outlook Therapeutics Inc (NASDAQ: OTLK) Key Stats
The company with the Market Capitalisation of 125.63 million has total of 23,406K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -58,980 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was 44,410 K.
